e-learning
resources
Virtual 2020
Pre-Congress Content
COPD and the impact of comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
S. Palli (Ridgefield, United States of America), C. Elliott (Eden Prairie, United States of America), B. Xie (Eden Prairie, United States of America), B. Chastek (Eden Prairie, United States of America), L. Bengston (Eden Prairie, United States of America)
Source:
Virtual Congress 2020 – COPD and the impact of comorbidities
Session:
COPD and the impact of comorbidities
Session type:
E-poster session
Number:
2469
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Palli (Ridgefield, United States of America), C. Elliott (Eden Prairie, United States of America), B. Xie (Eden Prairie, United States of America), B. Chastek (Eden Prairie, United States of America), L. Bengston (Eden Prairie, United States of America). Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs. 2469
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI)
Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity
Year: 2020
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B).
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - Assessment of physical functioning and handling with Tiotropium/Olodaterol (T/O) in patients with COPD requiring long-acting dual bronchodilation in an Italian cohort of patients.
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019
Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS)
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED).
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients.
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021
Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB)
Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring
Year: 2010
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021
Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept